Adding a medicine to the WHO model list of essential medicines

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 3, 2009, Pages 237-239

  Kishore, S O ^a   Herbstman, B J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESSENTIAL DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; WORLD HEALTH ORGANIZATION;

CARDIOVASCULAR DISEASES; DRUGS, ESSENTIAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, ORGANIZATIONAL; WORLD HEALTH ORGANIZATION;

EID: 60349109330     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.258     Document Type: Note

References (17)

1. Gaziano, T.A. Cardiovascular disease in the developing world and its cost-effective management. Circulation 112, 3547-3553 (2005).
2. World Health Organization. Shaping the Future (World Health Organization, Geneva, 2003).
3. Schwartlander, B., Grubb, I. & Perriens, J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 368, 541-546 (2006).
4. Zhang, X., Patel, A., Horibe, H., Wu, Z., Barzi, F., Rodgers, A. et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int. J. Epidemiol. 32, 563-572 (2003).
5. Verschuren, W.M., Jacobs, D.R., Bloemberg, B.P., Kromhout, D., Menotti, A., Aravanis, C. et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274, 131-136 (1995).
6. Cai, J., Pajak, A., Li, Y., Shestov, D., Davis, C.E., Rywik, S. et al. Total cholesterol and mortality in China, Poland, Russia, and the US. Ann. Epidemiol. 14, 399-408 (2004).
7. Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
8. Tan, C.E., Loh, L.M. & Tai, E.S. Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience. Singapore Med. J. 44, 635-638 (2003).
9. Muck, W., Unger, S., Kawano, K. & Ahr, G. Interethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br. J. Clin. Pharmacol. 45, 583-590 (1998).
10. Matsuzawa, Y., Kita, T., Mabuchi, H., Matsuzaki, M., Nakaya, N., Oikawa, S. et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ. J. 67, 287-294 (2003).
11. Law, M.R., Wald, N.J. & Rudnicka, A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326, 1423 (2003).
12. Ounpuu, S., Negassa, A. & Yusuf, S. INTER-HEART: a global study of risk factors for acute myocardial infarction. Am. Heart J. 141, 711-721 (2001).
13. US Food and Drug Administration. FDA approves generic simvastatin. FDA News 〈http://www.fda.gov/bbs/topics/NEWS/2006/NEW01394.html〉 (23 June 2006).
14. Management Sciences for Health (MSH). International Drug Price Indicator Guide 〈http://erc.msh.org〉 (2007).
15. Gaziano, T.A., Reddy, K.S., Paccaud, F., Horton, S. & Chaturvedi, V. Cardiovascular Disease (World Bank Group, Washington, DC, 2006).
16. Gaziano, T.A., Opie, L.H. & Weinstein, M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 368, 679-686 (2006).
17. Chemical Information Services. Directory of World Chemical Producers 〈http://www.chemicalinfo.com/products/dwcp/dwcp-overview.htm〉.